文献速递心外重症与机械循环支持

COMPETENCE试验:EVAHEART 2连续流左心室辅助装置

COMPETENCE Trial: The EVAHEART 2 continuous flow left ventricular assist device.
PubMed 文献 · J Heart Lung Transplant · 2022-10-19

COMPETENCE试验是一项前瞻性、多中心、随机、非劣效性研究,旨在评估EVAHEART 2左心室辅助装置(EVA2)对比HeartMate 3左心室辅助系统(HM3)治疗难治性晚期心力衰竭的非劣效性。主要终点为心脏移植或装置撤除后恢复生存、无致残性卒中、无重度右心衰竭的复合终点,随机比例为2:1(EVA2:HM3)。首例患者于2020年12月入组,目前已有25例受试者(EVA2组16例,HM3组9例)入组,安全性队列预计2022年第三季度完成入组并进行中期分析。

要点

  • COMPETENCE试验为前瞻性、多中心、随机、非劣效性研究,比较EVA2与HM3治疗难治性晚期心力衰竭。
  • 主要终点为心脏移植或装置撤除后恢复生存、无致残性卒中、无重度右心衰竭的复合终点,随机比例2:1(EVA2:HM3)。
  • 截至报告时,25例受试者已入组(EVA2组16例,HM3组9例),安全性队列预计2022年第三季度完成入组。

核心结论

  • EVA2的设计特征如新型流入插管和大血间隙可能改善临床结局,但需要进一步研究。
  • 正在进行的COMPETENCE试验旨在确定EVA2是否非劣效于HM3。

研究设计与样本

  • 前瞻性、多中心、随机、非劣效性研究,评估EVA2对比HM3治疗难治性晚期心力衰竭。
  • 随机比例为2:1(EVA2:HM3)。
  • 主要终点为心脏移植或装置撤除后恢复生存、无致残性卒中、无重度右心衰竭的复合终点。

主要发现

  • 首例患者于2020年12月入组。
  • 目前已有25例受试者入组(EVA2组16例,HM3组9例)。
  • 安全性队列预计2022年第三季度完成入组,届时将进行中期分析。
  • 短期队列(EVA2组92例)和长期队列预计分别于2023年底和2024年底完成。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • EVA2的设计特征可能改善临床结局,但需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuous flow left ventricular assist devices have improved outcomes in patients with end-stage heart failure that require mechanical circulatory support. Current devices have an adverse event profile that has hindered widespread application. The EVAHEART®2 left ventricular assist device (EVA2) has design features such as large blood gaps, lower pump speeds and an inflow cannula that does not protrude into the left ventricle that may mitigate the adverse events currently seen with other continuous flow devices. METHODS: A prospective, multi-center randomized non-inferiority study, COMPETENCE Trial, is underway to assess non-inferiority of the EVA2 to the HeartMate 3 LVAS when used for the treatment of refractory advanced heart failure. The primary end-point is a composite of the individual primary outcomes: Survival to cardiac transplant or device explant for recovery; Free from disabling stroke; Free from severe Right Heart Failure after implantation of original device. Randomization is in a 2:1 (EVA2:HM3) ratio. RESULTS: The first patient was enrolled into the COMPETENCE Trial in December of 2020, and 25 subjects (16 EVA2 and 9 HM3) are currently enrolled. Enrollment of a safety cohort is projected to be completed by third quarter of 2022 at which time an interim analysis will be performed. Short-term cohort (92 EVA2 subjects) and long-term cohort is expected to be completed by the end of 2023 and 2024, respectively. CONCLUSIONS: The design features of the EVA2 such as a novel inflow cannula and large blood gaps may improve clinical outcomes but require further study. The ongoing COMPETENCE trial is designed to determine if the EVA2 is non-inferior to the HM3.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Allen SR, Slaughter MS, Ahmed MM, et al. COMPETENCE Trial: The EVAHEART 2 continuous flow left ventricular assist device. J Heart Lung Transplant. 2022. PMID: 36347767. doi:10.1016/j.healun.2022.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。